What if the cure for obesity were hidden in a serpent's blood? That is the surprising avenue being explored by a team of American researchers, who have just published a major discovery: a molecule naturally present in the blood of the Burmese python is capable of significantly reducing appetite in obese mice, without triggering the side effects that tarnish the reputation of current anti-obesity medications.

The python, a metabolic marvel

The Burmese python (Python bivittatus) is an animal with extraordinary physiological capabilities. Able to ingest prey representing up to 25% of its own body weight, it can then fast for several consecutive months without losing muscle or developing metabolic disorders. Throughout that time, its body remains perfectly healthy.

This remarkable ability intrigued researchers at the University of Colorado Boulder (CU Boulder), in collaboration with teams from Stanford University and Baylor University. Their initial question: what biochemical mechanism allows the python to manage extreme cycles of feeding and fasting without harmful consequences for its health?

The pTOS molecule: an unexpected discovery

By analyzing the blood of pythons immediately after a copious meal, the scientists identified a marked spike in a molecule that had previously received little study: para-tyramine-O-sulfate, or pTOS. This molecule is the product of a remarkably simple chain of biochemical transformations:

• The digestive tract releases tyrosine, an amino acid found in animal proteins.
• Intestinal bacteria convert tyrosine into tyramine.
• The liver then transforms tyramine into pTOS.
• This compound travels to the brain, where it acts on the hypothalamus, the area responsible for regulating appetite.

In other words, after every meal, the python naturally secretes a molecule that tells it: "stop, that's enough." A powerful and effective satiety signal, arising directly from digestion.

Impressive results in mice

To test the effects of pTOS in mammals, the researchers administered the molecule to obese mice. The results, published in the journal Nature Metabolism on March 19, 2026, are encouraging: treated animals spontaneously reduced their food intake and lost an average of 9% of their body weight. Unlike other substances tested in this field, pTOS did not affect basal energy metabolism, organ size, or muscle mass.

It is on this last point that the discovery takes on its full importance: muscles are preserved. A considerable advantage over existing medications, some of which are associated with a problematic loss of lean mass.

A key advantage over GLP-1 medications

In recent years, GLP-1 analogues — including Ozempic (semaglutide) and Wegovy — have revolutionized the treatment of obesity. These medications, originally developed for type 2 diabetes, allow for significant weight loss. But they come with their share of drawbacks: nausea, vomiting, abdominal pain, slowed gastric emptying, and even concerning cases of muscle loss.

pTOS takes a radically different path. Where GLP-1s mainly act on the pancreas and stomach, pTOS directly targets the brain via the hypothalamus. In experiments conducted on mice, no gastrointestinal side effects were observed. A potentially major difference for the millions of patients who abandon their current treatments because of adverse effects.

"We found a molecule that speaks directly to the brain to say the body is satisfied, without going through the pathways that cause digestive discomfort," summarize the researchers from CU Boulder.

Toward a medication for humans?

The road is still long before a pTOS-based human treatment becomes available in pharmacies. For now, experiments are limited to mouse models, and clinical trials in humans have not yet begun. However, the researchers have already taken the initiative: they have founded a start-up, Arkana Therapeutics, tasked with translating these discoveries into concrete medical applications.

The molecule has several advantages for its pharmaceutical development: it is natural, derived from a simple metabolic pathway (and therefore potentially reproducible in the laboratory), and its mechanism of action is well identified. These characteristics in theory facilitate its optimization and formulation.

The intestinal microbiome, cornerstone of the discovery

A particularly interesting aspect of this research lies in the central role played by the intestinal microbiome. Without the intestinal bacteria that convert tyrosine into tyramine, there would be no pTOS. This discovery adds a new dimension to our understanding of the link between gut flora, brain, and weight regulation — an axis researchers call the gut-brain axis.

These findings reinforce the idea that the microbiome is not merely a simple actor in digestion, but a true metabolic partner, capable of influencing our appetite and eating behaviors through chemical signals. Understanding this axis could open other therapeutic avenues still unsuspected.

A breakthrough in the fight against obesity

Obesity today affects more than one billion people worldwide, according to the latest WHO data. Despite recent advances with GLP-1 medications, many patients cannot benefit from these treatments due to their side effects, high cost, or medical contraindications. Finding new molecules acting through different mechanisms is therefore a global public health priority.

The discovery of pTOS is part of a broader trend: drawing inspiration from living organisms — particularly animals with extreme metabolisms — to find solutions to human diseases. After lizard venom (at the origin of GLP-1s themselves, inspired by exenatide from the Gila monster), now the serpent enters the scene.

Nature, it seems, has not finished surprising us.